Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 333 restricted stock units (RSUs) to one newly-hired employee. The grant was made on September 30, 2025, under the company's 2022 Inducement Stock Incentive Plan.

The RSUs will vest over a three-year period, with one-third of the units vesting annually on the grant date anniversary. Vesting is contingent upon the employee's continued service with Karyopharm.

News Market Reaction – KPTI

+1.29%

5 alerts

+1.29% Session close to close

+7.5% Peak in 7 hr 4 min

$53.98M Market Cap

0.7x Rel. Volume

In the Oct 2 session, KPTI gained 1.29%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.5% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302571436.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What type of stock compensation did Karyopharm (KPTI) grant to its new employee?

Karyopharm granted 333 restricted stock units (RSUs) to one newly-hired employee on September 30, 2025.

What is the vesting schedule for Karyopharm's (KPTI) new RSU grant?

The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the September 30, 2025 grant date.

Under which plan were the Karyopharm (KPTI) RSUs granted?

The RSUs were granted under Karyopharm's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

What are the conditions for the Karyopharm (KPTI) RSU grant to vest?

The RSU grant requires the employee to maintain continued service as an employee or service provider to Karyopharm through the applicable vesting dates.